Psychiatric Nurse

Softer surgery volumes, hospital woes dampened UHS' Q3 earnings. An increasing shift toward outpatient surgeries and slower-than-expected ramps to profitability at some of its hospitals dinged Universal Health Services earnings in the third quarter. Published Oct. 29, 2026 Dive brief: * Hospital operator Universal Health Services said it now expects earnings results for 2026 to end up on the lower range of its expectations after surgeries declined and some of its hospitals struggled in the third quarter. * Although hospital admissions rose overall, UHS executives said on a call with investors Wednesday that an increasing consumer shift to outpatient care dinged surgeries in its inpatient-heavy portfolio. * Other hospital chains have called out declining surgeries, including HCA Healthcare, as more patients lose insurance and others abstain due to cost. Dive insight: Patients have been increasingly getting surgeries in outpatient facilities, including ambulatory care centers and physician offices, enticed by lower costs and more convenient care options. Hospital operators have been attempting to capitalize on that shift, buying outpatient facilities and integrating them into their networks. UHS's portfolio, which includes 30 inpatient acute care hospitals and over 340 inpatient behavioral health facilities, skews more inpatient. Most of its medical admissions, meaning those that aren't surgeries, come through UHS' emergency rooms and surgeries tend to be elective, CFO Steve Filton said. Surgeries are a lucrative service line for operators, and a decline in volumes can ding earnings: In the third quarter, UHS' same-facility surgeries declined 0.7% over the prior year period. At the same time, medical admissions "significantly outpaced" surgery volumes, according to Filton, (acute care volumes increased 4.3%), which brought down UHS' net revenue per admissions. Although surgeries have been shifting more to outpatient, elective procedures across the board have been declining as patients postpone care due to cost and more people lose health insurance. Both inpatient and outpatient surgeries declined by similar levels, according to Filton. UHS reported $308 million in net income during the third quarter, an approximately 17% decrease from the prior year. Revenues increased over 5% to $4.7 billion. Slower-than-expected progress on some of its new hospitals also pressured UHS' earnings in the quarter. In Washington D.C., a hospital that UHS built in partnership with the city is struggling to become profitable. Executives said Cedar Hill Regional Medical Center is expected to break even on its finances in the first half of 2027, after executives again pushed back the timeline for profitability. Cedar Hill was originally supposed to break even during the first half of this year before the timeline was pushed back to the fourth quarter of 2026. Filton said Cedar Hill's physicians are in the early stages of developing their networks in an area that was historically a healthcare desert. In the meantime, the facility is losing roughly $30 million per quarter, executives said. Florida-based Alan B. Miller Medical Center, an acute care hospital that UHS opened in May, is also causing a drag on UHS' earnings. The hospital is in the "early stages" of ramping up volumes, but executives said they expect that trend to accelerate entering the busier flu and winter season. The hospital, located in Palm Beach Gardens, Florida, was a $15 million drag in the third quarter, executives said. Struggles with those two hospitals, combined with another behavioral health facility in Texas that lost its Medicare certification, are expected to contribute $80 million to $100 million in losses this year, Filton said. "Taken together, Palm Beach Gardens and Cedar Hill are progressing, but their pace of maturation remains an important factor in the timing of margin improvement for the acute care segment," Filton said. Executives said they expect UHS to end up at the lower end of its guidance range this year. Last quarter, UHS said it expected to notch $18.5 billion to $18.76 billion in revenue this year, and $2.6 billion to $2.7 billion in pretax income minus some other costs. On the exchange front, executives said patients formerly insured on Affordable Care Act plans are still going uninsured at almost a 1-to-1 rate, causing a predicted loss of slightly less than $25 million in the quarter. Exchange volumes were down 17% from the prior year. The decline in exchange volumes, and rise in uninsured patients, has caused billion-dollar losses at other hospital chains. UHS has less exposure than some larger operators, and expects to lose about $85 million from the trend this year.

UHS signals 2027 Medicaid supplemental headwind of $175M-$200M while reiterating 2026 outlook toward low end. Oct 28, 2026, 12:41 PM ET Universal Health Services, Inc. (UHS) Stock AI-Generated Earnings Calls Insights Earnings Call Insights: Universal Health Services (UHS) Q3 2026 Management view. * "Overall, underlying performance in the third quarter reflected sequential improvement in several areas. Acute Care demand remained favorable. Behavioral Health volumes demonstrated an increase relative to recent quarters, and labor trends continue to moderate." (CEO, President & Director Marc Miller) * "Third quarter results included certain items that were not reflected in the outlook we provided with our second quarter results in July." (CEO, President & Director Marc Miller) Miller highlighted items including "the benefit from the expansion of existing Medicaid supplemental programs in several states, partially offset by other nonrecurring litigation and transaction costs." * "In Behavioral Health, we completed the Talkspace acquisition on August 17 and began executing the integration plan." (CEO, President & Director Marc Miller) Miller described a phased integration focused on technology to improve transitions of care, referral flows into Talkspace for therapy and medication management, and development of "a virtual intensive outpatient program, or IOP." * "At Laurel Ridge... we currently expect during 2027." (CEO, President & Director Marc Miller) Miller said work toward recertification continued and that Q3 financial impact was consistent with the company's July outlook assumptions. * "The company reported adjusted EPS of $5.22 for the third quarter of 2026, representing a decline of 8% year-over-year." (Executive VP, CFO & Secretary Steve Filton) Filton also said, "Third quarter adjusted EBITDA less NCI was $625 million as compared to $671 million in the third quarter of 2025." Outlook. * "We are reiterating the financial and operating forecast ranges issued with our second quarter results in July." (Executive VP, CFO & Secretary Steve Filton) Filton added, "we currently expect results to be towards the lower end of these ranges," citing year-to-date trends and the ramp of Washington, D.C. and Palm Beach Gardens. * On early 2027 framing (ahead of formal February guidance), Filton said, "Cumulatively, these facilities are expected to contribute operating losses of $80 million to $100 million in 2026," referring to Laurel Ridge and the two acute care de novos. * Filton also provided a preliminary regulatory headwind estimate: "As it relates to Medicaid supplemental payments, we estimate the 2027 headwind will be approximately $175 million to $200 million." * On exchanges, Filton said, "Annualizing the second half 2026 run rate would create a $15 million headwind in 2027," while noting open enrollment could change the outcome. Financial results. * Filton said Q3 included a net favorable $12 million impact from three items not contemplated in July guidance: "$47 million of supplemental Medicaid benefit," "$26 million of additional professional and general liability reserves," and "$8.5 million of transaction-related costs associated with the Talkspace acquisition." * Filton said, "Excluding these items, adjusted EBITDA less NCI was below our internal expectations," driven by "a slower-than-expected ramp-up at our de novo hospitals and softer-than-expected surgical trends." * Acute Care same-facility demand remained positive: "adjusted admissions... increased 4.9%," and "emergency department visits increased 4.6%," while "surgeries decreased 0.7%." (Executive VP, CFO & Secretary Steve Filton) * Behavioral Health same-facility metrics improved modestly: "same-facility net revenue increased 4.0%," with "a 2.1% increase in... revenue per adjusted patient day" and "a 2.1% increase in... adjusted patient days." (Executive VP, CFO & Secretary Steve Filton) * Cash flow and capital allocation remained active. Filton said, "Third quarter cash generated from operating activities was $637 million," capex was "$214 million," and "we acquired 1.35 million of our own shares... at a total cost of $242 million." Q&A. * Albert Rice, UBS Investment Bank: asked for "puts and takes for next year" including DPP and exchange headwinds; Executive VP, CFO & Secretary Filton: said the company will give "full comprehensive 2027 guidance in February," and estimated "the 2027 headwind... approximately $175 million to $200 million," while citing exchange run-rate "$15 million headwind in 2027." * Ann Hynes, Mizuho: asked what is "driving that slower ramp" at the two acute facilities; Executive VP, CFO & Secretary Filton: said Cedar Hill has had "busy emergency room activity," but "what has lagged has been a busier surgical and procedural schedule," attributing it to "a lack of physician infrastructure" in Ward 7 and 8; for Palm Beach Gardens, he cited opening "in the beginning of the summer" after "construction delays." * Justin Lake, Wolfe Research: asked to break down losses and Laurel Ridge timeline; CEO, President & Director Miller: "we don't have an exact date in 2027"; Executive VP, CFO & Secretary Filton: said Laurel Ridge prior pretax income was "in the $20 million, $25 million range," current losses "$5 million or $10 million a quarter," Cedar Hill "roughly $10 million a month," and Palm Beach Gardens "about $15 million in this quarter." * Kevin Fischbeck, BofA Securities: pressed on what's causing "acceleration" of surgical shift; Executive VP, CFO & Secretary Filton: "I don't know that I have a great explanation," but described compounding impacts in GI, including difficulty "to get GIs to cover our emergency rooms," leading to diversion. Sentiment analysis. * Analysts' tone was slightly negative to pressing around de novo ramps, surgical softness, and 2027 headwinds, with questions like "what's driving that loss versus your expectations" (Ann Hynes, Mizuho) and requests to explain the "acceleration" in the shift out of hospital surgeries (Kevin Fischbeck, BofA). * Management tone was neutral to slightly positive in prepared remarks, emphasizing sequential improvement and integration progress, but more cautious on forward visibility in Q&A, including "we don't have an exact date in 2027" (CEO, President & Director Miller) and "I don't know that I have a great explanation" (Executive VP, CFO & Secretary Filton). * Versus last quarter, management continued to emphasize exchange pressure consistency and de novo ramp timing, but Q3 included more explicit preliminary 2027 sizing (Medicaid supplemental headwind and facility-loss recovery potential) than was discussed in Q2. Quarter-over-quarter comparison. * Q3 reiterated the July (Q2) 2026 forecast ranges, with Filton adding that results were expected "towards the lower end," whereas Q2 introduced an "updated 2026 forecast... in a range of $2.61 billion to $2.72 billion" for adjusted EBITDA less NCI. (Executive VP, CFO & Secretary Filton) * Talkspace shifted from "pending" in Q2 ("we expect to close in mid-August") to closed in Q3 ("completed the Talkspace acquisition on August 17"), with management moving from integration planning to execution and phased rollout. (CEO, President & Director Marc Miller) * De novo timing expectations moved out at Cedar Hill: in Q3, Filton said the hospital is now expected to reach "operational breakeven in the first half of 2027 compared with our prior expectations of the fourth quarter of 2026." Risks and concerns. * Filton identified "softer-than-expected surgical trends" and "slower-than-expected ramp-up at our de novo hospitals" as key operational risks to near-term margins. * On 2027 regulatory risks, Filton flagged "reductions to Medicaid supplemental funding," potential "Medicaid work requirements," and uncertainty tied to exchange enrollment, while stating a baseline assumption that "a vast majority of Behavioral Health patients and a meaningful portion of our Acute Care patients could be exempt" under medical frailty exemptions. Final takeaway. Management reiterated 2026 guidance ranges but said results were tracking toward the lower end as de novo hospitals mature and surgical mix remains pressured. Executives framed Talkspace as a phased integration aimed at building outpatient continuity and referral pathways over "the next 12 to 24 months," while also previewing material 2027 swing factors: potential recovery of an estimated $80 million to $100 million of 2026 operating losses at Laurel Ridge and the de novos, alongside an estimated $175 million to $200 million Medicaid supplemental headwind and a $15 million exchange run-rate headwind if current trends persist. Fresh Stock Ideas, Every Day Explore diverse investing perspectives with daily analysis from experts across the market. More on Universal Health Services. Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.

UHS revenue climbs 5.3% while third-quarter profit slides (NYSE: UHS). What happened. Universal Health Services, Inc. (NYSE: UHS) grew third-quarter revenue 5.3% to $4.73 billion, but net income attributable to the company fell to $308.7 million. That compares with $373.0 million in the third quarter of 2025, when revenue was $4.50 billion. Diluted earnings per share were $5.22, down from $5.86. Over the first nine months, revenue rose 7.7% to $13.87 billion from $12.88 billion. Net income attributable to UHS slipped to $1.02 billion from $1.04 billion. Diluted earnings per share still rose to $16.86 from $16.07. The weighted diluted share count fell to 60.241 million from 64.897 million. Key numbers. | Metric | Latest | Change | Source | | Q3 net revenues | $4.73 billion | from $4.50 billion, +5.3% | SEC 8-K | | Q3 net income attributable to UHS | $308.7 million | from $373.0 million, -17.2% | Calculated from SEC 8-K | | Q3 Adjusted EBITDA net of NCI | $624.6 million | from $670.6 million, -6.9% | Calculated from SEC 8-K | | Nine-month diluted EPS | $16.86 | from $16.07, +4.9% | Calculated from SEC 8-K | | Nine-month operating cash flow | $1.48 billion | from $1.29 billion, +14.9% | SEC 8-K | | Nine-month share repurchases | $689.6 million | / | SEC 8-K | Where costs outran revenue. Costs grew faster than sales in the quarter. By OptimistFi's calculation, salaries, wages and benefits rose 6.7% to $2.21 billion. Other operating expenses rose 10.1% to $1.43 billion. Income from operations fell to $454.4 million from $521.7 million. Adjusted EBITDA net of NCI, which excludes other income and expense, was $624.6 million against $670.6 million. Its margin on net revenues slipped to 13.2% from 14.9%. The nine-month figures show the same gap. Revenue rose by about $987.8 million, OptimistFi calculates. Adjusted EBITDA net of NCI rose by only about $39.1 million, to $1.95 billion from $1.91 billion. Its margin was 14.1%, down from 14.8%. Demand was not the weak spot. At same-facility acute care hospitals, adjusted admissions rose 4.9% in the quarter, but net revenue per adjusted admission fell 1.7%. In behavioral health, adjusted admissions rose 2.5% and revenue per adjusted admission rose 1.7%. Items that moved the quarter. Two items outside the company's 2026 forecast partly offset each other. A $47 million pre-tax gain, net of provider taxes, came from higher Medicaid supplemental payments, mainly in Washington, D.C. and California. A $26 million pre-tax charge raised reserves for self-insured professional and general liability claims, mostly because of the tentative Cumberland Litigation settlement. Together they added about $21 million before tax. A year earlier, similar items added about $55 million. That included $90 million of Washington, D.C. reimbursements and a $35 million reserve charge. So profit fell even with a net benefit from these items, though a smaller one than in 2025. UHS reached the tentative Cumberland settlement in August 2026. It would resolve all outstanding claims by current claimants. Terms are confidential, and final releases and court approvals are pending. UHS believes its commercial excess insurance covers much of the amount and its reserves cover the rest. Cash, buybacks and debt. Cash generation was the stronger side. Net cash from operating activities rose 14.9% to $1.48 billion over nine months from $1.29 billion. The filing lists a favorable $178 million change in accounts receivable. It was offset by an unfavorable $179 million in other working capital, which the filing ties to timing of payments. UHS repurchased 3.915 million shares over nine months for about $689.6 million, an average of about $176 a share. In the third quarter alone it bought 1.35 million shares for about $242.1 million, about $179 a share. About $735.4 million of authorization remained on Sept. 30. Spending and borrowing rose as well. Cash paid for acquisitions of businesses and property was $1.00 billion, against $47.8 million a year earlier. The Talkspace, Inc. acquisition closed in August 2026. Total debt was $5.71 billion on Sept. 30. Third-quarter net interest expense was $56.3 million against $38.4 million. The $1.5 billion revolver had $1.19 billion of available capacity. Why it matters. OptimistFi has argued that UHS creates value if essential local demand keeps turning into reimbursement, operating leverage and cash despite payer and labor pressure. The quarter backs the demand and cash parts. It does not show operating leverage, because margins fell in both the quarter and the nine months. The Medicaid gain comes with a caveat. It came from supplemental payment programs. The filing warns that failure to renew such programs beyond their scheduled end dates could push 2026 results away from the company's forecast. It also says legislation adopted July 4, 2025 may reduce revenues and raise uncompensated care as its provisions take effect. Higher interest expense and debt leave less room for error if costs keep growing faster than sales. The result for the case is mixed. What's next. UHS holds its investor conference call at 8:00 a.m. Eastern on Oct. 28. The test is how management explains wage and other operating costs growing faster than revenue, and whether it addresses the margin decline. The next quarterly report will show whether the adjusted EBITDA margin stops falling and whether buybacks continue under the remaining authorization. Final release agreements and court approvals are still needed to complete the Cumberland settlement. From optimistfi perps. Sources. * SEC Form 8-K, Exhibit 99.1 earnings release dated Oct. 27, 2026 - Third-quarter and nine-month 2026 results, share repurchases, balance sheet, cash flow and legal proceedings update. * SEC filing Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research. Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.